Leong-Poi Howard

Northern Therapeutics, Inc. operate as a biotechnology company. It develops a novel method for selective gene transfer and regenerative cell therapy targeting the pulmonary vasculature with the hope of repairing damaged lung tissues in a number of respiratory and cardiopulmonary conditions, including PAH, Acute Respiratory Distress Syndrome (ARDS), Cystic Fibrosis and Emphysema. The company was founded in 2000 and is headquartered in Montréal, Canada.